Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Phenmetrazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 5/20 | 1.00 |
| ▸ | SLC6A3 known ✓ | Q01959 | 5/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.72 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 5/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenmetrazine SCHEMBL33984 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A3ADRA1AHTR2BCHRNA7 | |
| Phenmetrazine SCHEMBL15159761 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A3ADRA1AHTR2BCHRNA7 | |
| Phenmetrazine SCHEMBL15154744 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A3ADRA1AHTR2BCHRNA7 | |
| Phenmetrazine SCHEMBL8094204 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A3ADRA1AHTR2BCHRNA7 | |
| Phenmetrazine SCHEMBL15159760 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A3ADRA1AHTR2BCHRNA7 | |
| Phenmetrazine SCHEMBL22462307 | 0.98 | SLC6A2 (0.96) | SLC6A2SLC6A3ADRA1AHTR2BCHRNA7 | |
| Phenmetrazine SCHEMBL121536 | 0.98 | SLC6A2 (0.96) | SLC6A2SLC6A3ADRA1AHTR2BCHRNA7 | |
| Phenmetrazine SCHEMBL3341647 | 0.90 | SLC6A2 (0.81) | SLC6A2SLC6A3ADRA1AHTR2BCHRNA7 | |
| SCHEMBL1666720 | 0.89 | SLC6A2 (0.80) | SLC6A2SLC6A3ADRA1AHTR2BCHRNA7 | |
| Phenmetrazine SCHEMBL28570473 | 0.86 | SLC6A2 (0.74) | SLC6A2SLC6A3ADRA1AHTR2BCHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2880 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3706762-B1 | N4-HYDROXYCYTIDINE DERIVATIVE AND ANTI-VIRAL USES RELATED THERETO | UNIV EMORY (US) | 2024-10-16 | — | — | EP | claimed |
| EP-3897641-B1 | TREATMENT OF MOVEMENT DISORDERS | CONTERA PHARMA AS (DK) | 2023-11-15 | — | — | EP | claimed |
| EP-3446681-B1 | ABUSE RESISTANT CAPSULE | SCHERER TECHNOLOGIES LLC R P (US) | 2020-12-23 | — | — | EP | claimed |
| EP-2459228-B1 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2020-03-04 | — | — | EP | claimed |
| EP-2237799-B1 | PRODRUG COMPRISING A SELF-CLEAVABLE LINKER | ASCENDIS PHARMA AS (DK) | 2019-04-10 | — | — | EP | claimed |
| EP-2968129-B1 | ABUSE RESISTANT CAPSULE | SCHERER TECHNOLOGIES LLC R P (US) | 2018-09-05 | — | — | EP | claimed |
| EP-2459171-B1 | Long acting insulin composition | SANOFI AVENTIS DEUTSCHLAND (DE) | 2017-06-21 | — | — | EP | claimed |
| EP-1833467-B1 | PHARMACEUTICAL COMPOSITIONS FOR SLEEP DISORDERS | COLLEGIUM PHARMACEUTICAL INC (US) | 2016-08-03 | — | — | EP | claimed |
| EP-1349835-B1 | (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE, COMPOSITIONS AND USES THEREOF | EUTHYMICS BIOSCIENCE INC (US) | 2016-03-30 | — | — | EP | claimed |
| EP-1825851-B1 | Combination therapy for effecting weight loss and treating obesity | VIVUS INC (US) | 2015-07-22 | — | — | EP | claimed |
| EP-1560585-A1 | DOSAGE FORM THAT IS SAFEGUARDED FROM ABUSE | Grünenthal GmbH (DE) | 2005-08-10 | — | — | EP | claimed |
| EP-1558257-A1 | DOSAGE FORM THAT IS SAFEGUARDED FROM ABUSE | Grünenthal GmbH (DE) | 2005-08-03 | — | — | EP | claimed |
| EP-1558221-A1 | DOSAGE FORM THAT IS SAFEGUARDED FROM ABUSE | Grünenthal GmbH (DE) | 2005-08-03 | — | — | EP | claimed |
| EP-1515702-A1 | ABUSE-PROTECTED ADMINISTRATION FORM | Grünenthal GmbH (DE) | 2005-03-23 | — | — | EP | claimed |
| WO-2004037230-A1 | DOSAGE FORM THAT IS SAFEGUARDED FROM ABUSE | Grünenthal GmbH (DE) | 2004-05-06 | — | — | WO | claimed |
| WO-2004037260-A1 | DOSAGE FORM THAT IS SAFEGUARDED FROM ABUSE | Grünenthal GmbH (DE) | 2004-05-06 | — | — | WO | claimed |
| WO-2004037259-A1 | DOSAGE FORM THAT IS SAFEGUARDED FROM ABUSE | Grünenthal GmbH (DE) | 2004-05-06 | — | — | WO | claimed |
| WO-2003105808-A1 | ABUSE-PROTECTED ADMINISTRATION FORM | Grünenthal GmbH (DE) | 2003-12-24 | — | — | WO | claimed |
| EP-0110955-B1 | BRAIN-SPECIFIC DRUG DELIVERY | UNIV FLORIDA (US) | 1995-08-23 | — | — | EP | claimed |
| EP-0152379-A2 | Process for preparing pharmaceutical compositions containing unilamellar liposomes | CIBA-GEIGY AG (CH) | 1985-08-21 | — | — | EP | claimed |